Fig. 4From: Body mass index is not associated with survival outcomes and immune-related adverse events in patients with Hodgkin lymphoma treated with the immune checkpoint inhibitor nivolumabReceiver operating characteristic (ROC) analysis of body mass index (BMI) to identify patients who progressed during nivolumab monotherapy. The red line represents the reference line of predictive usefulnessBack to article page